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Since the Precision Medicine Initiative was launched in 
2015, tremendous progress has been documented in this 
field [1]. Specifically, non-coding RNA (ncRNA) has been 
getting increased attention as it has been implicated in 
contributing to different diseases, including cancer [2]. 
ncRNAs are known to regulate gene expression at the 
transcriptional and post-transcriptional levels, influencing 
chromatin remodeling and signal transduction. 
Deregulation of ncRNAs has an impact on the impairment 
of physiological programs, driving cells in cancer 
development [2].   
In recent years, ncRNAs have emerged as a previously 
unappreciated class of gene expression modulators that 
regulate various cellular processes, especially modulating 
gene expression in various cancers. Although most ncRNA 
research focuses on cancers, some scientists have been 
exploring their relationship to other diseases. For example, 
Lucafò M and colleagues found that ncRNA growth arrest-
specific transcript 5 (GAS5) could mediate tissue damage 
in inflammatory bowel disease by modulating the 
expression of Matrix metalloproteinases (MMPs) [3]. Apart 
from that, the small molecule YK-4-279 blocks chimeric 
transcription factor EWS-FLI1 activity in Ewing sarcomas 
via inhibiting the expression of ncRNA Highly Upregulated 
in Liver Cancer (HULC), which help researchers to 
interpret the effect path of medicine [4]. 
Recent breakthroughs in genome engineering, such as 
CRISPR/Cas9 system, present a useful tool to advance 
ncRNA research [5, 6].  RNA-programmed genome 
editing using CRISPR/Cas9 is an ideal platform to 
genetically manipulate ncRNA molecules to mechanisti-
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cally and functionally dissect endogenous ncRNA 
networks in diseases. 
Efficiency in vivo delivery, however, has long been a 
major challenge as currently available lipid nanoparticles 
(LNPs) can induce liver damage and stimulate an immune 
response [7]. However, some new technologies seem to 
provide a better solution, such as LUNAR®-mediated 
delivery of RNA into cells developed by a commercial 
company, Arcturus Therapeutics in California [8]. 
Recent advances on ncRNA are likely to promote 
precision medicine, and results can be expected in the near 
future. However, before becoming accessible to patients, 
ncRNA has a long way to go. 
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